Physician profile
Charles Dunn
NPI 1477976082
$8,697.42
in general payments reported to CMS, 2019-2025
19 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $494 · 2022: $462 · 2023: $6,066 · 2024: $885 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,536 · Food and Beverage: $2,430 · Travel and Lodging: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,536.00 |
| Food and Beverage | $2,430.07 |
| Travel and Lodging | $775.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,713.19 | 2022-2025 | |
| Abbvie INC. | $734.36 | 2021-2025 | Skyrizi, Rinvoq |
| Pfizer INC. | $398.13 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $381.09 | 2021-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $283.81 | 2021-2025 | Adbry, Anzupgo |
| Amgen INC. | $263.63 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $200.79 | 2021-2025 | |
| Janssen Biotech, INC. | $121.75 | 2022-2025 | Tremfya |
| Dermavant Sciences, INC. | $96.71 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $76.78 | 2024-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $62.66 | 2025 | |
| Incyte Corporation | $56.71 | 2022-2023 | Opzelura |
| Janssen Scientific Affairs, LLC | $53.34 | 2022 | |
| Galderma Laboratories, L.P. | $36.14 | 2025 | Nemluvio |
| Paratek Pharmaceuticals, INC. | $31.82 | 2021-2025 | Nuzyra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $22.05 | 2025 | |
| Almirall LLC | $20.09 | 2025 | Klisyri |
| Ucb, INC. | $18.45 | 2022 | |
| Mayne Pharma Commercial LLC | $17.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.